Appointment of Ernie
De Paolantonio to Chief
Financial Officer Further Strengthens Leadership
Team
GRAND
RAPIDS, Mich., Feb. 15,
2023 /PRNewswire/ -- Corium Pharma Solutions, Inc.
(CPSI), a leading, full-service contract development and
manufacturing organization specializing in novel drug delivery
technologies for prescription drug and consumer products including
transdermal modalities, has named Ernie De
Paolantonio as Chief Financial Officer. This announcement
follows the recent appointments of several industry veterans,
Mark Sirgo as Chief Executive
Officer, Kevin Ostrander as Chief
Business Officer and Dr. Niraj
Vasisht as Chief Technology Officer.
Appointment of Ernie De Paloantonio to
Chief Financial Officer Further Strengthens CPSI's Leadership
Team
Ernie brings over 30 years of financial and business experience
in the pharmaceutical industry including both private and public
commercial and manufacturing companies. Most recently, he was Chief
Financial Officer of Journey Medical Corporation, a commercial
stage dermatology company. Prior to that, he held several
leadership positions throughout his career including Chief
Financial Officer at Teligent, Inc., a specialty generic
pharmaceutical company, Fortovia Therapeutics Inc., a privately
held healthcare company, Chief Financial Officer, Secretary and
Treasurer of BioDelivery Sciences International, Inc., a public
specialty pharmaceutical company and Chief Financial Officer of
CorePharma LLC, a privately held specialty generic company.
As CFO, Ernie will have responsibility for both finance and
information technology.
"I am pleased to be able to work with Ernie again as we look to
grow this promising specialty development and manufacturing
business. Ernie will bring his over thirty years of financial
experience across a spectrum of pharmaceutical companies to help
drive the growth of Corium Pharma Solutions. He will play an
instrumental role working closely with myself, members of the
leadership team, and our investors on our long-term growth strategy
and its execution," said Mark Sirgo,
CEO of CPSI, in making the announcement.
Founded in 1995 in Grand Rapids,
Michigan, Corium Pharma Solutions has maintained
longstanding partnerships with multinational Fortune 500 companies
and pharmaceutical businesses alike. CPSI currently manufactures a
variety of over the counter and prescription products, including
Proctor & Gamble Co's (NYSE: PG) entire Crest Whitestrips
franchise, Agile Therapeutics, Inc.'s (NASDAQ: AGRX) Twirla®, and
Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal
donepezil patch.
About Corium Pharma Solutions
Headquartered in Grand Rapids,
Michigan, Corium Pharma Solutions is a leading, full-service
contract development and manufacturing organization specializing in
novel drug and consumer product delivery technologies. With a track
record spanning nearly 30 years, the company offers end-to-end
solutions to its partners, from formulation and product development
work, through commercial-scale manufacturing and packaging. The
company's success is enabled by its state-of-the-art facilities,
highly tenured operational leadership, and proprietary drug
delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma
Solutions is jointly owned by B-FLEXION and Webster Equity
Partners. Prior to the CPSI transaction with Webster Equity
Partners in October 2022, Gurnet
Point Capital, an affiliate of B-Flexion, led the original
investment in Corium Pharma Solutions through a take-private
transaction in October 2018.
About Gurnet Point Capital & B-FLEXION
Gurnet Point Capital, an affiliate of B-FLEXION, is a leading
healthcare fund that invests in de-risked life sciences companies.
Gurnet Point primarily focuses on businesses that have high growth
potential in the late product development and commercialization
stages of their evolution. These companies become partners not just
because of their capacity to generate economic value, but also
because of their potential to deliver social impact. Gurnet Point's
team of highly experienced industry executives works closely with
its portfolio companies, with an active approach driving
operational transformation and outsized returns.
www.gurnetpointcapital.com/
B-FLEXION is a private, entrepreneurial investment firm,
partnering with sophisticated capital to meet the shared goal of
delivering exceptional value over the generations, while also
contributing positively to society. The company oversees
growth-oriented operating businesses and asset managers, always
with an 'active owner' philosophy. B-FLEXION invests across a wide
range of industries, including healthcare. Gurnet Point Capital, an
affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences
investment strategy.
https://www.bflexion.com/
About Webster Equity Partners
Founded in 2003, Webster is a
private equity firm that focuses on high impact growth strategies
that seek to deliver optimal outcomes for our investors, portfolio
companies and the communities that we serve. Our mission is to
deliver superior returns to our partners through the investment in
and development of purpose driven patient-centric healthcare
organizations dedicated to providing best of class clinical care
and service to their patients.
https://websterequitypartners.com/
Contact
Gartman PR
(202) 413-4226
View original
content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html
SOURCE Corium Pharma Solutions Inc.